Results 71 to 80 of about 221,455 (333)

Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec, Elif Everest, Melih Tutuncu, Ugur Bilge, Sabahattin Saip, Ugur Uygunoglu, Aksel Siva   +6 more
wiley   +1 more source

Kinetics of Rituximab Excretion into Urine and Peritoneal Fluid in Two Patients with Nephrotic Syndrome

Case Reports in Nephrology, 2017
Clinical observations suggest that treatment of Rituximab might be less effective in patients with nephrotic range proteinuria when compared to nonnephrotic patients.
Klaus Stahl, Michelle Duong, Anke Schwarz, A. D. Wagner, Hermann Haller, Mario Schiffer, Roland Jacobs   +6 more
doaj   +1 more source

Rituximab Therapy in Adults with Refractory Symptomatic Immune Thrombocytopenia: Long-Term Follow-Up of 15 Cases

Turkish Journal of Hematology, 2017
Objective: This paper prospectively evaluates the long-term followup [mean +- standard deviation (SD) duration: 89.7+-19.4 months] data of 15 patients (13 females and 2 males) with refractory symptomatic immune thrombocytopenia (ITP) treated with ...
Fehmi Hindilerden, Ipek Yönal Hindilerden, Mustafa Nuri Yenerel, Meliha Nalçacı, Reyhan Diz Küçükkaya   +4 more
doaj   +1 more source

Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost‐effectiveness analysis

Cancer Medicine, 2020
Background The aim of the study was to evaluate the cost‐effectiveness of lenalidomide plus rituximab vs rituximab alone in patients with relapsed or refractory indolent lymphoma.
Peng‐Fei Zhang, Dan Xie, Feng Wen, Qiu Li   +3 more
doaj   +1 more source

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia

New England Journal of Medicine, 2014
BACKGROUND Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical conditions are less able to undergo standard chemo-therapy.
R. Furman, J. Sharman, S. Coutre, B. Cheson, J. Pagel, P. Hillmen, J. Barrientos, A. Zelenetz, T. Kipps, I. Flinn, P. Ghia, H. Eradat, T. Ervin, N. Lamanna, B. Coiffier, A. Pettitt, Shuo Ma, S. Stilgenbauer, P. Cramer, Maria Aiello, D. Johnson, L. Miller, Daniel Li, T. Jahn, R. Dansey, M. Hallek, S. O'Brien   +26 more
semanticscholar   +1 more source

Rituximab for High-Risk, Mature B-Cell Non-Hodgkin’s Lymphoma in Children

New England Journal of Medicine, 2020
BACKGROUND Rituximab added to chemotherapy prolongs survival among adults with B-cell cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non-Hodgkin’s lymphoma are limited. METHODS We conducted an open-label, international,
V. Minard-Colin, A. Aupérin, M. Pillon, G. A. Amos Burke, D. Barkauskas, K. Wheatley, Rafael Delgado, S. Alexander, A. Uyttebroeck, C. Bollard, J. Zsiros, M. Csóka, B. Kazanowska, A. Chiang, R. Miles, A. Wotherspoon, P. Adamson, G. Vassal, C. Patte, T. Gross   +19 more
semanticscholar   +1 more source

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.

The Lancet Oncology, 2021
BACKGROUND Copanlisib, an intravenous pan-class I PI3K inhibitor, showed efficacy and safety as monotherapy in patients with relapsed or refractory indolent non-Hodgkin lymphoma who had received at least two therapies. The CHRONOS-3 study aimed to assess
M. Matasar, M. Capra, M. Özcan, F. Lv, Wei Li, E. Yáñez, Katya Sapunarova, Tong-Yu Lin, Jie Jin, W. Jurczak, A. Hamed, Ming-Chung Wang, R. Baker, I. Bondarenko, Qing-Yuan Zhang, Ji-Feng Feng, K. Geissler, M. Lazaroiu, G. Saydam, Á. Szomor, K. Bouabdallah, R. Galiulin, T. Uchida, L. M. Soler, A. Cao, F. Hiemeyer, A. Mehra, B. Childs, Yuan-Kai Shi, P. Zinzani   +29 more
semanticscholar   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source

Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study.

Neurology, 2021
OBJECTIVE To determine whether rituximab is safe and potentially beneficial, warranting further investigation in an efficacy trial for acetylcholine receptor antibody-positive generalized MG (AChR-Ab+ gMG).
R. Nowak, C. Coffey, J. Goldstein, M. Dimachkie, M. Benatar, J. Kissel, G. Wolfe, T. Burns, M. Freimer, S. Nations, V. Granit, A. Smith, D. Richman, E. Ciafaloni, M. Al-lozi, Laura Sams, Dian-Na Quan, E. Ubogu, Brenda Pearson, Aditi Sharma, Jon W. Yankey, Liz Uribe, M. Shy, A. Amato, R. Conwit, K. O'Connor, D. Hafler, M. Cudkowicz, R. Barohn   +28 more
semanticscholar   +1 more source